Partner at Novo Holdings · Joined 2022
View Live Interactive Profile →Daniel O'Connell joined Novo Holdings Venture Investments in 2022 as a Partner based in the San Francisco office. Before Novo Holdings he was Executive Director, Equity and Venture Capital/Corporate Development at Bristol Myers Squibb, responsible for managing direct equity investments and LP positions in venture funds and leading the evaluation and acquisition of public companies. Before BMS he was an Investment Director with Arix Bioscience and a Senior Associate with OrbiMed, and earlier Associate Director, Cardiovascular Research at Arisaph Pharmaceuticals. He holds an undergraduate degree in chemistry and mathematics from MIT and an MD and PhD from Tufts University.